Listed

IGC Pharma, Inc.: Form 10-Q for the period ended Jun 30, 2018

Filed with the SEC on Aug 3, 2018 and accepted by EDGAR at Aug 2, 2018, 20:24 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2018-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2018-04-01 to 2018-06-30$1.5mus-gaap:Revenues
Cost of revenue3 months2018-04-01 to 2018-06-30$1.4mus-gaap:CostOfRevenue
Research and development3 months2018-04-01 to 2018-06-30$37.4kus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2018-04-01 to 2018-06-30$553.6kus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2018-04-01 to 2018-06-30−$511.7kus-gaap:OperatingIncomeLoss
Income tax3 months2018-04-01 to 2018-06-30$0us-gaap:IncomeTaxExpenseBenefit
Net income3 months2018-04-01 to 2018-06-30−$512.3kus-gaap:NetIncomeLoss
Diluted EPS3 months2018-04-01 to 2018-06-30−$0.02us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow3 months2018-04-01 to 2018-06-30−$534.8kus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2018-04-01 to 2018-06-30$3.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2018-06-30$1.0mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2018-06-30$4.2mus-gaap:AssetsCurrent
Total assetsAt period end2018-06-30$11.5mus-gaap:Assets
Current liabilitiesAt period end2018-06-30$3.7mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2018-06-30$3.9mus-gaap:Liabilities
Shareholders' equityAt period end2018-06-30$7.6mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001185185-18-001341. Last ingested by Listed: Nov 6, 2026, 16:27 ET. Listed shows no prices and gives no investment advice.